Among patients with T2D and DPN, some with nonpainful DPN developed neuropathic pain over a 5-year period while others with painful DPN experienced relief.

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

While it is not a common condition, Guillain-Barré Syndrome (GBS) is garnering increased interest from the broader medical diagnostics industry as new cases are reported worldwide each year and linked ...

Grifols revises forecasts upward after strong Q1, targeting €10B sales and €2.9B EBITDA. Click here to read my analysis of ...

Sanofi (NASDAQ: SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

People with any type of substance use disorder (SUD) stand a 24% higher risk of having an unplanned hospital readmission within 30 days of a previous ...

The National Organization for Rare Disorders (NORD®) is honoring a distinguished group of industry leaders and individuals for their contributions to help improve the lives of more than 30 million ...

Nervous system involvement was common among a cohort of patients with AAV, with these individuals showing less severe renal impairment.